1. Background Information
Virolab, Inc. (the Company) was incorporated in the
state of Delaware on May 4, 2010 under the name Accelerated Acquisitions X, Inc. The Company was formed as a shell company
with no operations while it sought new business opportunities. On March 8, 2011, we entered into a Licensing
Agreement, pursuant to which the Company received an exclusive, non-transferrable worldwide license to specified
technology, patents, intellectual property, know-how, trade secret information, clinical trial protocols and data, as well as commercial
||an investigational therapeutic vaccine for the human papillomavirus (HPV) and HPV-related cancers and|
||a diagnostic blood test for HPV.|
As a result of entering into the licensing agreement and undertaking
efforts into the research and development its product candidates, the Company ceased to be a shell company. The Company changed
its name to Virolab, Inc. on April 5, 2011. The Company operates in one reportable business segment, the development and commercialization
of products to improve human healthcare.
The Company is currently in the development stage. All activities
of the Company to date relate to its organization and acquiring rights to its product candidates. None of the Companys product
candidates have been approved for sale in any countries.